Fengyuan pharmaceutical purchased 50 million yuan of new drugs for lung cancer

Fengyuan pharmaceutical announced on the evening of October 22 that the company and the University of science and technology of China signed the technology transfer contract for the "human recombinant interleukin-12 drug" (rhIL-12 drug for short) developed by the research and development team of IL-12, the Key Laboratory of natural immunity and chronic diseases, Chinese Academy of Sciences According to the contract, CUHK is responsible for completing all technical data required by "rhIL-12 drug clinical trial application acceptance" on time according to the latest national drug registration management measures and the latest relevant technical guidelines for drug research, and transferring the technical results to the company as this node The total amount of the technology transfer fee is 50 million yuan According to the milestone payment method in the drug technology transfer, the company will pay in seven phases according to the research process According to the company, the rhIL-12 drug transferred this time is mainly used for the treatment of lung cancer Considering the indications, treatment costs and replaceable drugs and other factors, the market scale is expected to be considerable In addition, rhIL-12 is a broad-spectrum cellular immune enhancer, which is not only effective for lung cancer, but also for other malignant tumors and viral diseases, and has a broad market prospect News extended Fengyuan pharmaceutical's 240 million purchase of Pushu pharmaceutical to expand its business scale Fengyuan Pharmaceutical (000153) announced the report of issuing shares to purchase assets and raise supporting funds on the evening of October 22 The company plans to issue shares to Pushi group to purchase 100% of its shares in Pushi pharmaceutical; the transaction price is 248 million yuan, and the issuing price of shares issued by the company to purchase assets is 7.81 yuan / share, and the number of shares issued is 3183670 shares At the same time, no more than 10 specific investors will be offered non-public shares to raise supporting funds of no more than 82.8815 million yuan The issue price of shares of supporting funds raised by non-public shares will not be less than 7.03 yuan / share, and the number of shares issued will not be more than 11.7897 million shares After the completion of the transaction, the company will hold 100% of the shares of Pushi pharmaceutical Established in July 2007 with a registered capital of 10 million yuan, Pushi pharmaceutical's business scope covers the production, technical consultation, R & D and transfer of small volume injections, technical consultation, R & D and transfer of drugs approved by the state such as eyedrops and rinses, and the production, technical consultation, R & D and transfer of medical devices (class I) 6854 operating rooms, emergency rooms, diagnosis and treatment rooms Financial data shows that as of June 30, 2014, the total assets of the subject company are 219 million yuan, the net assets are 205 million yuan, the operating revenue is 224900 yuan, and the net profit is - 7844600 yuan; in 2013, the total assets of the subject company are 18272700 yuan, the net assets are - 2747000 yuan, the operating revenue is 170000 yuan, and the net profit is - 7241000 yuan The company explained that the main reason for the continuous loss of the target company was that since the establishment of pushpharma, only a small number of medical devices have been produced due to the reasons of drug variety approval and preparation of new GMP certification, and the production line of main pharmaceutical equipment has not been officially put into production until April 2014, when the GMP certification of small volume injection production line of plastic ampoules was obtained Although at present, pusher pharmaceutical has obtained GMP certification and started the production and sales of plastic ampoule clindamycin phosphate and other products, there is still a risk of sustained loss in the short term.